CA2526899A1 - Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol - Google Patents

Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol Download PDF

Info

Publication number
CA2526899A1
CA2526899A1 CA002526899A CA2526899A CA2526899A1 CA 2526899 A1 CA2526899 A1 CA 2526899A1 CA 002526899 A CA002526899 A CA 002526899A CA 2526899 A CA2526899 A CA 2526899A CA 2526899 A1 CA2526899 A1 CA 2526899A1
Authority
CA
Canada
Prior art keywords
mice
aminoisobutyric acid
treatment
beta
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002526899A
Other languages
English (en)
French (fr)
Inventor
Bernard Fromenty
Philippe Letteron
Karima Begriche
Anissa Igoudjil
Caroline Maisonneuve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2526899A1 publication Critical patent/CA2526899A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002526899A 2003-04-18 2004-04-15 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol Abandoned CA2526899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2003/001463 WO2004091598A1 (en) 2003-04-18 2003-04-18 Use of beta-aminoisobutyric acid for the treatment of diseases linked to the accumulation of triglycerides and cholesterol
IBPCT/IB03/01463 2003-04-18
PCT/IB2004/001166 WO2004091599A1 (en) 2003-04-18 2004-04-15 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol

Publications (1)

Publication Number Publication Date
CA2526899A1 true CA2526899A1 (en) 2004-10-28

Family

ID=33187198

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002526899A Abandoned CA2526899A1 (en) 2003-04-18 2004-04-15 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol

Country Status (7)

Country Link
US (1) US20060167098A1 (enExample)
EP (1) EP1615630A1 (enExample)
JP (1) JP2006523672A (enExample)
AU (1) AU2003226582A1 (enExample)
BR (1) BRPI0409456A (enExample)
CA (1) CA2526899A1 (enExample)
WO (2) WO2004091598A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367072B2 (en) * 2006-12-08 2013-02-05 Polifenoles Naturales, S.L. Composition for treating obesity and method of using the same
RU2013126706A (ru) 2010-11-15 2014-12-27 Рамот Ат Тель-Авив Юниверсити Лтд. Дипептидные аналоги для лечения состояний, ассоциированных с образованием амилоидных фибрилл
CN105250256A (zh) * 2015-10-16 2016-01-20 南京医科大学 β-氨基异丁酸在制备抗糖尿病药物中的应用
KR20180126053A (ko) * 2016-03-30 2018-11-26 마이크로바이오 컴퍼니 엘티디. 면역 체크포인트 조절제 및 공생 미생물군에 의한 발효 산물로의 병용 암 치료법
JP2019131488A (ja) * 2018-01-29 2019-08-08 静岡県公立大学法人 Ｖｃａｍ−１発現抑制剤、ｍｃｐ−１発現抑制剤、炎症性疾患改善用組成物、加工食品又は飲料
US20220347141A1 (en) * 2019-09-17 2022-11-03 Yale University Methods of treating phosphate concentration disorders with l-baiba
EP4297742A4 (en) * 2021-04-14 2024-10-09 Nanjing Nutrabuilding Bio-Tech Co., Ltd. COMPOSITIONS AND METHODS FOR PROMOTING GLYCOGEN SYNTHASE ACTIVITY AND INCREASING GLYCOGEN STORAGE CAPACITY
CA3223282A1 (en) * 2021-06-22 2022-12-29 Ronghua YI Administration of baiba to increase benefit of losing weight of intermittent fasting
CN115606809A (zh) * 2021-10-08 2023-01-17 南京纽邦生物科技有限公司 通过施用β-氨基异丁酸模拟热量限制的生物学益处的方法和组合物
CN116059195A (zh) * 2022-01-28 2023-05-05 南京纽邦生物科技有限公司 用于提高运动表现或预防或缓解疲劳的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4453941A (en) * 1980-12-29 1984-06-12 Board Of Overseers Of Goshen College Composition and process for producing pigmentation in hair or skin
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
FR2701948B1 (fr) * 1993-02-22 1996-07-26 Exsymol Sa Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires.
JPH07101984A (ja) * 1993-09-30 1995-04-18 Suntory Ltd ペプチド誘導体
JPH107553A (ja) * 1996-03-21 1998-01-13 Toutoushiyu Seizo Kk 生体内ラジカル消去剤及び抗潰瘍剤

Also Published As

Publication number Publication date
JP2006523672A (ja) 2006-10-19
US20060167098A1 (en) 2006-07-27
EP1615630A1 (en) 2006-01-18
AU2003226582A1 (en) 2004-11-04
WO2004091598A1 (en) 2004-10-28
WO2004091599A1 (en) 2004-10-28
BRPI0409456A (pt) 2006-04-18

Similar Documents

Publication Publication Date Title
CA2331408C (en) Fatty analogues for the treatment of obesity, hypertension and fatty liver
CA2784836A1 (en) Improved method of administering .beta.-hydroxy-.beta.-methylbutyrate (hmb)
US20060167098A1 (en) Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol
US20080027139A1 (en) Use of Alpha-Ketoglutarate and Related Compounds
US6441041B1 (en) (-)-hydroxycitric acid for the prevention of osteoporosis
JP3858055B2 (ja) 抗肥満剤及び脂質代謝改善剤
CN120583948A (zh) 施用dhb增加间歇禁食的减重益处
CA3223282A1 (en) Administration of baiba to increase benefit of losing weight of intermittent fasting
US7388030B2 (en) Suppressors of anemia and appetite suppressors and methods for suppressing anemia and suppressing appetite
JP2007262017A (ja) ピペコリン酸含有抗糖尿病組成物
JP3915999B2 (ja) 抗肥満剤及び脂質代謝改善剤
EP1221868A1 (en) Dietary supplement
AU2022332335A1 (en) Compositions and methods for preventing or reducing the risk of metabolic syndrome
HK1107018B (en) Use of alpha-ketoglutarate and related compounds for lowering plasma lipids
HK1053265A (en) Novel fatty acid analogues for the treatment of hypertension
MXPA06002948A (en) Enhanced method of treatment of growth disorders
HK1051967A (en) Novel fatty acid analogues for the treatment of fatty liver
HK1116999A (en) A method and composition for nutritionally improving glucose control and insulin action
HK1034912B (en) Novel fatty analogues for the treatment of obesity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead